Wilmington Savings Fund Society FSB Reduces Holdings in Amgen Inc. $AMGN

Wilmington Savings Fund Society FSB decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 51,576 shares of the medical research company’s stock after selling 5,627 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Amgen were worth $14,555,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in AMGN. Laurel Wealth Advisors LLC lifted its holdings in Amgen by 27,765.8% during the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares during the last quarter. Norges Bank purchased a new position in shares of Amgen in the second quarter worth about $1,663,726,000. Capital World Investors increased its stake in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares in the last quarter. National Bank of Canada FI raised its position in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Amgen by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after buying an additional 841,117 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 1.4%

Shares of NASDAQ:AMGN opened at $361.13 on Wednesday. The firm has a fifty day moving average price of $359.26 and a two-hundred day moving average price of $326.77. The company has a market cap of $194.67 billion, a price-to-earnings ratio of 25.38, a PEG ratio of 3.63 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Analyst Upgrades and Downgrades

Several research firms recently commented on AMGN. Rothschild & Co Redburn raised their price objective on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft increased their target price on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Daiwa Securities Group boosted their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Finally, HSBC reissued a “buy” rating and set a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $354.00.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.